Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Breast Dis ; 42(1): 315-318, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37807774

RESUMEN

ER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.


Asunto(s)
Neoplasias de la Mama , Humanos , Femenino , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/genética , Neoplasias de la Mama/tratamiento farmacológico , Receptores de Estrógenos/genética , Pronóstico , Receptores de Progesterona/genética , Receptor ErbB-2 , Biomarcadores de Tumor
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA